CD44 and breast cancer: CSCs exhibit unique surface markers (e.g., CD44 + /CD24 − /low in breast cancer [133], CD44 + /CD133 + in prostate cancer [53]) and upregulated signaling pathways like Hedgehog-Gli1 and TGFβ1 that are minimally active in normal progenitors.